Antiviral effect of lithium chloride on feline calicivirus in vitro

Arch Virol. 2015 Dec;160(12):2935-43. doi: 10.1007/s00705-015-2534-8. Epub 2015 Aug 5.

Abstract

Feline calicivirus (FCV) is a highly contagious pathogen that causes oral and upper respiratory tract disease in cats. Despite widespread vaccination, the prevalence of FCV remains high. Furthermore, a high gene mutation rate has led to the emergence of variants, and some infections are lethal. To date, there is no effective antiviral drug available for treating FCV infection. Here, we show that lithium chloride (LiCl) effectively suppresses the replication of FCV strain F9 in Crandell-Reese feline kidney (CRFK) cells. The antiviral activity of LiCl occurred primarily during the early stage of infection and in a dose-dependent manner. LiCl treatment also inhibited the cytopathic effect. LiCl treatment exhibited a strong inhibitory effect against a panel of other two reference strains and two recent FCV isolates from China. These results demonstrate that LiCl might be an effective anti-FCV drug for controlling FCV disease. Further studies are required to explore the antiviral activity of LiCl against FCV replication in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology*
  • Caliciviridae Infections / drug therapy
  • Caliciviridae Infections / veterinary*
  • Caliciviridae Infections / virology
  • Calicivirus, Feline / drug effects*
  • Calicivirus, Feline / genetics
  • Calicivirus, Feline / physiology
  • Cat Diseases / drug therapy
  • Cat Diseases / virology*
  • Cats
  • Cell Line
  • Lithium Chloride / pharmacology*
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • Lithium Chloride